Conference Coverage

Implementation of a Hematology VA-ECHO Program

Abstract: 2018 AVAHO Meeting


 

Purpose/Rationale: Lack of access to a hematology specialist is a barrier to care for veterans in rural and underserved areas. In light of the increasingly short supply of sub-specialists, there is a need to provide hematology education and outreach to primary care providers within the VA system.

Background: The ECHO program (Extension for Community Healthcare Outcomes) is a well-established and successful platform that audibly and visually links an area specialist to primary care providers and interdisciplinary team members, allowing for two-way specialty consultation combined with continuing education. Overall, our service network (VISN 20) has provided specialty education to more than 10 specialties and 171 clinical sites (26% rural or highly rural) through the VA-ECHO program. In fiscal year 2016, VISN 20 estimated that over 280,000 potential patient travel miles saved as a result of VA-ECHO.

Methods/Approach: As we could not identify an existing Hematology VA-ECHO program within VISN 20, nor to our knowledge nationally, we sought to develop and implement a Hematology VA-ECHO program based at the Puget Sound VA (Seattle, WA).

Results: We delivered an introductory 3-part VA-ECHO series to assess demand and solicit feedback about Hematology VA-ECHO. Session topics were iron deficiency anemia, polycythemia, and deep vein thrombosis/pulmonary embolism. We had participation from 17 sites in 9 states; 10 sites within VISN 20. Attendees included pharmacists, MDs, APRNs and RNs. We averaged 20 participants per session and welcomed 43 unique participants over 3 sessions. The vast majority (94%) of respondents (n=34) agreed or strongly agreed that the content in the sessions were relevant to their practice and 80% anticipated changing their practice as a result of session participation

Conclusion/Implications: A successful Hematology VA-ECHO program stands to de-monopolize specialty knowledge and help primary providers evaluate and manage common hematologic abnormalities, especially in underserved areas. We aim to expand Hematology VA-ECHO to include 8-9 sessions over the next calendar year. Uptake of Hematology VA-ECHO at additional VA sites in different geographical areas would help further increase hematology access for primary providers.

Recommended Reading

Do Erythropoiesis-Stimulating Agents Have a Risk Evaluation and Mitigation Strategy? (FULL)
AVAHO
Open Clinical Trials for Patients With Renal Cell Carcinoma (FULL)
AVAHO
Colorectal cancer: New observations, new implications
AVAHO
VA and NCI Join to Provide Leading-Edge Cancer Treatment
AVAHO
FDA warns against azithromycin in blood or lymph node cancers
AVAHO
New chronic lymphocytic leukemia guidelines from the UK
AVAHO
Advances in Hematology and Oncology (August 2018)
AVAHO
Could An Antibiotic Be the Next Great Oncologic Drug?
AVAHO
Abstracts Presented at the 2018 AVAHO Annual Meeting (Digital Edition)
AVAHO
Cardiovascular Effects of Tyrosine Kinase Inhibitors in Advanced Renal Cell Carcinoma (RCC) Patients at VA San Diego Healthcare System (VASDHS)
AVAHO